BenevolentAI is a clinical-stage AI drug discovery company that combines advanced AI and machine learning with science to discover and develop novel and more effective medicines.
BenevolentAI has raised €92M across 1 funding round from 1 investor, most recently a round in Feb 2018. Based in London, UK; active in Healthtech. The company has exited (2021). Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-02-01 | Other | €92M | Woodford Investment Management | View deal → |
